BioNeutral Appoints Wayne Stratton to Advisory Board

NEWARK, N.J., Jan. 10, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced the appointment of Wayne Stratton to its Advisory Board. Mr. Stratton is based in Louisville, Kentucky, has been a member/owner of Jones, Nale & Mattingly PLC, a full-service accounting and auditing practice since 1970, and has extensive experience serving on corporate and civic boards.

Mr. Stratton comes to BioNeutral with outstanding qualifications. He is a certified public accountant in Kentucky, accredited in Business Valuation by the American Institute of Certified Public Accountants (AICPA), a Certified Forensic Accountant, Certified Fraud Examiner and a Credentialed Cooperative Director through National Rural Electric Cooperative Association.

His corporate board experience includes current service as Chairman of the Board of East Kentucky Power Cooperative where is the former Audit Committee Chairman and has served as Director since 1990, Director of National Rural Utilities Cooperative Finance Corporation, Director of Shelby Energy Cooperative since 1987, Director of ACES Power Marketing since 2004, Director of Shelbyville Municipal Water & Sewer Commission since 2000 and Director of Republic Bancorp, a $2.8 billion bank traded on NASDAQ, since 1995, where he currently serves as the Audit Committee Chairman and Audit Committee Financial Expert.

Mr. Stratton is also the former team captain for AICPA peer reviews of other accounting firms and former board member of Kentucky Higher Education Assistance Authority (1985 to 2001) where as Chairman for eight years, he participated in various finance transactions. He served on the AICPA Uniform Accountancy Act Committee and is the past president of the Kentucky Society of CPAs.

Mr. Stratton will participate in the Advisory Board’s activities relating to Kentucky and other states in which BioNeutral seeks to do business. As previously announced, BioNeutral recently conducted meetings with government and healthcare organizations in Kentucky and is positioning the Company’s products to be distributed to healthcare facilities in the state upon regulatory and hospital association approval.

“We are extremely pleased to welcome Wayne to our advisory board,” said Stephen J. Browand, President and CEO of BioNeutral. “Wayne brings a superb level of experience and is well connected in the Kentucky business community. Wayne will be a helpful resource to us as we work to establish ourselves as a major player in the Kentucky and other US healthcare markets.”

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral’s products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company’s filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company’s technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company’s data and findings. BioNeutral’s antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the UnitedStates.

SOURCE BioNeutral Group, Inc.